about the author

Max Bayer

Pharma Reporter

mbayer@endpointsnews.com

author articles

Large vac­cine mak­ers stand by their in­vest­ments de­spite US head­winds

Last month
Pharma
FDA+

FDA asks No­vavax for post-mar­ket­ing da­ta of its Covid vac­cine, de­lay­ing ap­proval

Last month
Pharma
FDA+

CMS would ab­sorb 340B drug dis­count pro­gram un­der leaked HHS re­or­ga­ni­za­tion pro­pos­al

Last month
Pharma
FDA+

CDC ad­vi­sors broad­en RSV vac­cine rec­om­men­da­tions to at-risk adults in their 50s

Last month
R&D

At ACIP hear­ing, CDC says it's 'scrap­ing' to re­spond to measles out­break; FDA com­ments on No­vavax halt

Last month
Pharma
FDA+

Trump phar­ma tar­iffs inch clos­er as ad­min­is­tra­tion con­firms US trade probe

Last month
R&D
Pharma

CDC vac­cine ad­vi­sors are set to meet this week af­ter two-month de­lay and scruti­ny from Kennedy

Last month
R&D
Pharma

Vac­cines, obe­si­ty drugs, job cuts: Take­aways from RFK Jr.'s first net­work in­ter­view as HHS chief

Last month
People
Pharma

Phar­ma CEOs warn EU of po­ten­tial ‘ex­o­dus to the US’ as trade war con­tin­ues

Last month
Pharma
Manufacturing

Min­neso­ta fed­er­al judge dis­miss­es chal­lenge from Ab­b­Vie, As­traZeneca to state's 340B law

Last month
Pharma
Law

‘This is self-in­flict­ed’: Leerink’s David Risinger on the mar­ket shock and hits to bio­phar­ma

Last month
People
FDA+

RFK Jr. won’t tes­ti­fy be­fore key Sen­ate com­mit­tee this week on HHS over­haul

Last month
Pharma
FDA+

No­vavax’s held-up ap­proval pack­age may sig­nal warn­ing for Covid vac­cine mak­ers

Last month
R&D
Pharma

FDA will con­sol­i­date to five 'shared ser­vices of­fices,' ac­cord­ing to memo to Hill staffers

Last month
Pharma
FDA+

Chaot­ic tar­iff roll­out leaves as many ques­tions as an­swers for drug­mak­ers

Last month
Pharma
Manufacturing

FDA cuts stir buy­er’s re­morse for some bio­phar­ma lead­ers, once ex­cit­ed by Trump

Last month
Pharma
Cell/Gene Tx

Q&A: John Crow­ley warns biotech is 'dan­ger­ous­ly close' to break­ing, as tar­iff threat, mar­kets bat­ter in­dus­try

Last month
People
Pharma

‘It’ll be a chal­lenge’: BIO chief Crow­ley ad­dress­es seis­mic FDA over­haul

Last month
People
Pharma

FDA sets new date for opi­oid-fo­cused ad­vi­so­ry meet­ing af­ter ear­li­er de­lay

Last month
FDA+

Ex­clu­sive: Tran­scend notch­es Phase 2 win to treat PTSD, in­vig­o­rat­ing bud­ding neu­ro­plas­to­gen class

Last month
R&D

Lykos’ in­ter­im CEO is set to step down

Last month
R&D
Pharma

Blue­bird gets new M&A bid, seek­ing to top pri­vate eq­ui­ty of­fer

Last month
Deals
R&D

Ex­elix­is’ pri­ma­ry can­cer drug wins FDA ap­proval for neu­roen­docrine tu­mors

Last month
R&D
Pharma

Trump tar­iffs would in­crease costs for al­most every bio­phar­ma com­pa­ny, sur­vey claims

2 months ago
Pharma
First page Previous page 12345 Next page Last page
A service from the Financial Times